The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial - Sandercock, P; Wardlaw, J M; Lindley, R IIST-3 collaborative group (Lancet, 2012)
et al.